Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The promising activity of Bortezomib as single agent in low grade lymphoma patients in small
studies has led to a number of larger multicenter trials with Bortezomib in combination with
Rituximab in mantle-cell lymphoma, follicular lymphoma and marginal zone lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Collaborators:
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte Fondazione Italiana Linfomi ONLUS University of Turin, Italy